IL33 and systemic sclerosis: The IL-33 inhibitor (CNTO-7160), which is currently being examined in clinical trials for asthma and atopic dermatitis, may be employed as a new therapy for fibrosis in patients with SSc, since anti-fibrotic effects have been observed on the lung [165,166].